6,542 followers
New research: BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival: Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory… #oncology ht